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E-mail address: mark.lindsay@manchester.ac.uk (MWe have previously reported that IL-b-induced miR-146a and miR-146b expression negatively reg-
ulates IL-8 and RANTES release in human alveolar A549 epithelial cells. To determine the intracellu-
lar pathways that regulate this response, we demonstrate IL-1b-induced activation of the nuclear
factor (NF)-jB, extracellular regulated kinase (ERK)-1/2, c-jun N-terminal kinase (JNK)-1/2 and
p38 mitogen activated kinase (MAP) kinase pathways. Subsequent pharmacological studies show
that IL-1b-induced miR-146a, IL-8 and RANTES production was regulated via NF-jB and JNK-1/2
whilst miR-146b expression was mediated via MEK-1/2 and JNK-1/2. These divergent intracellular
pathways likely explain the differential expression and biological action of the miR-146 isoforms.
Crown Copyright  2009 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
miRNA-Mediated RNA interference has been identiﬁed as a no-
vel mechanism that regulates gene expression at the translational
level [1,2]. These short RNA sequences of 20–23 nucleotides are
produced by the processing of full length mRNA-like transcripts
[3,4]. They are believed to either repress mRNA translation or re-
duce mRNA stability following imperfect binding between the
miRNA and the miRNA-recognition elements (MRE) within the 30
untranslated region (UTR) of target genes. Speciﬁcity of the miRNA
is thought to be primarily mediated by the ‘seed’ region that is
localized between residues 2–8 at the 50 end of the mature miRNA
[5–7].
The innate immune response provides the initial defense mech-
anism against infection by external pathogens such as bacteria,
fungi and viruses. One of the best characterized families of recep-
tors involved in the activation of the innate immune response are
the Toll like/interleukin-1 (TL/IL-1) receptors which, in humans,
can be subdivided into the Toll-like receptors (TLR) that are com-
posed of 11 members (named TLR-1 to TLR-11) and the interleukind by Elsevier B.V. on behalf of Fede
cation and Research Centre,
r M23 9LY, UK. Fax: +44 161
.A. Lindsay).(IL)-1 receptors that have 10 members [8,9]. The TLRs recognize
conserved molecules within bacteria, fungi and viruses whilst the
IL-1 receptors are activated by the pro-inﬂammatory cytokines,
interleukin (IL)-1a, IL-1b, IL-18 and IL-33 [9]. Agonism of TL/IL-1
receptors stimulates the production of multiple inﬂammatory
mediators including the chemokines, IL-8 and RANTES. This is
thought to be mediated through activation of multiple intracellular
signalling pathways that includes nuclear factor (NF)-jB, which
under basal conditions is localized within the cytoplasm attached
to inhibitor-jBa (IjBa). Degradation of IjBa following the phos-
phorylation by I-jB kinase-2 (IKK-2) has been shown to result in
the nuclear translocation of activated NF-jB and the subsequent
transcription of multiple inﬂammatory mediators [10]. Additional
pathways include the mitogen activated kinase cascades that ter-
minate at extracellular regulated kinase (ERK)-1/2, c-jun N-termi-
nal kinase (JNK)-1/2 and p38 MAP kinase.
Signiﬁcantly, recent studies have identiﬁed miRNA-mediated
RNA interference as a potentially novel mechanism that regulates
the immune response [11,12]. In particular, rapid increases in miR-
NA-146 and miRNA-155 expression has been demonstrated in im-
mune cells following activation of members of the TL/IL-1 receptor
family [13–18]. Of relevance, we have previously reported rapid
induction of miR-146a and miR-146b expression in IL-1b-stimu-
lated human alveolar A549 epithelial cells and showed that these
miRNAs attenuated the release of the inﬂammatory chemokines,ration of European Biochemical society. All rights reserved.
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146 but not miR-146b has been reported in inﬂammatory diseases
such as psoriasis [20], rheumatoid arthritis [21–23] and osteoar-
thritis [24,25]. Changes in miR-146a and miR-146b expression
and/or binding have also been implicated in the metastatic and
proliferative response associated with the development of papil-
lary thyroid carcinoma (PTC) [26–28], cervical cancer [29], ovarian
cancer [30], breast cancer [30–32], pancreatic cancer [31] and
prostate cancer [31,33].
However, despite studies demonstrating their differential
expression and importance in physiological and pathological re-
sponses little is known regarding the intracellular pathways that
regulate miR-146a and miR-146b expression. A number of previ-
ous reports have suggested that miR-146a transcription is regu-
lated by NF-jB, although no studies have yet examined the role
of the MAP kinases [13,19,34–36]. For this reason, we have used
a pharmacological approach to investigate the role of IKK-2, which
is an upstream activator of NF-jB and the mitogen activated ki-
nases, MEK-1/2, JNK-1/2 and p38 MAP kinase following IL-1b-
induced miR-146a and miR-146b expression in human alveolar
A549 epithelial cells.2. Materials and methods
2.1. Cell studies
Human alveolar epithelial A549 cells were grown in DMEM
containing 10% FCS and 2 mM L-glutamine and then plated at
75% conﬂuence in 96-, 24- or 6-well plates, cultured for an addi-
tional 1 h in the presence or absence of the indicated concentra-
tions of TPCA-1 (an IKK-2 inhibitor), PD098059 (a MEK-1/2
inhibitor), SP600125 (a JNK-1/2 inhibitor) and SB 203580 (a p38
MAP kinase inhibitor) and then stimulated with 1 ng/ml of IL-1b
for the indicated times (see below). All inhibitors were obtained
from Calbiochem.
2.2. Measurement of IL-8 and RANTES release
A549 cells were plated in 96-well plates and stimulated for 24 h
with IL-1b (1 ng/ml). The levels of IL-8 and RANTES in the superna-
tant were determined by DuoSet ELISA (R&D Systems) according to
the manufacturer’s instructions.
2.3. Measurement of miRNA expression
Total RNA was extracted using the mirVanaTM miRNA isolation
kit (Ambion Europe) according to the manufacturer’s instructions
from A549 cells that had been plated in 24-well plates and stimu-
lated with IL-1b (1 ng/ml) for 24 h. RNA was eluted in 50 ll RNase-
free water (Promega UK, Southampton, UK) and stored at 70 C.
RNA content and purity was measured using a BioTek PowerWave
XS (SSi Robotics, Tustin, CA, USA) spectrophotometer. miR-146a
and miR-146b expression in total RNA extracts were determined
by two-step TaqMan reverse transcription polymerase chain reac-
tion protocol (RT-PCR), normalized to 18S, as previously described
[17]. The separate well, 2(DDCt) method [37] was used to deter-
mine relative-quantitative levels of individual miRNAs, and these
were expressed as the fold-difference to the relevant controls.
2.4. Western blotting
Proteins were extracted at the indicated times from A549 cells
that had been plated in 6-well plates as previously described [38].
Samples were separated upon 10% SDS–PAGE gels (Invitrogen)
and transferred to nitrocellulose (Amersham Ltd.). Protein (5–10 lg) were detected by Western blotting using a rabbit anti-JNK-
1/2 (56G8), rabbit anti-IjBa (44D4), rabbit anti-p38 MAP antibody,
rabbit anti-ERK-1/2 antibody (137F5), rabbit anti-phospho-p38
MAP kinase (Thr180/Tyr182) antibody, rabbit anti-phospho-ERK-
1/2 (Thr202/Tyr204) antibody (D13.14.4E), and a rabbit anti-phos-
pho-JNK-1/2 (Thr183/Tyr185) antibody (81E11) that were
purchased from New England Biolabs. All primary antibodies were
used a concentration of 1:1000 or 1:2000 and were incubated over-
night. Labelling of the ﬁrst antibody was detected using relevant
secondary antibodies conjugated to HRP (Dako Ltd.) and detected
using ECL reagents (Amersham Ltd., UK).
2.5. Statistical analysis
Statistical changes in IL-8, RANTES, miR-146a and miR-146b
expression were determined using either a two-tailed Student’s
t-test or ANOVA with P set to 0.05 using Prism 4 for Windows (ver-
sion 4.03).3. Results
3.1. IL-1b-induced activation of the NF-jB and MAP kinase pathways
Prior to examining the action of the inhibitors, we determined
whether IKK-2 and the MAP kinase pathways were activated in
alveolar A549 epithelial cells following exposure to IL-1b. Phos-
phorylation of IjBa by activated IKK-2 results in its dissociation
from NF-jB and then rapid degradation following ubiquitination.
Activation of IKK-2 and NF-jB was indicated through measure-
ment of the total IjBa levels in A549 cells by Western blotting
which showed a rapid and transient loss in IjBa expression within
10 min of IL-1b exposure that returned at 60–90 min (Fig. 1). Acti-
vation of the MAP kinases pathways was also conﬁrmed by Wes-
tern blotting using phospho-antibodies that recognize activated
ERK-1/2 (Thr202/Tyr204), JNK-1/2 (Thr183/Tyr185) and p38 MAP
kinase (Thr180/Tyr182) (Fig. 1). From Fig. 1, it can be seen that
IL-1b-induced the rapid activation of ERK-1/2, JNK-1/2 and p38
MAP kinase, in which the levels of phosphorylations were in-
creased at 5 min and remained elevated throughout the 120 min
period.
3.2. Effect of pharmacological inhibitors upon IL-1b-induced
chemokine release and miR-146 expression
We have previously shown that IL-1b-induced both miR-146a
and miR-146b expression and the release of the pro-inﬂammatory
chemokines, IL-8 and RANTES [19]. To determine the role of these
intracellular pathways in regulating these IL-1b-induced re-
sponses, we examined the action of the selective pharmacological
inhibitors TPCA-1 (IKK-2 inhibitor) [39,40], PD098059 (an inhibitor
of ERK kinase-1/2 or MEK-1/2, an upstream activator of ERK-1/2)
[41,42], SP600125 (JNK-1/2 inhibitor) [43,44] and SB 203580
(p38 MAP kinase inhibitor) [45,46].
As previously reported, IL-1b stimulation of human alveolar
A549 epithelial cells induced both miR-146a and miR-146b expres-
sion and the release of IL-8 and RANTES at 24 h (Fig. 2). Examina-
tion of the DCT values (versus 18S) obtained by RT-PCR indicated
that basal miR-146a and miR-146b expression was identical at
15.6 ± 0.3 (n = 12) and 15.1 ± 0.2 (n = 12), respectively. Following
IL-1b exposure, measurement of the relative change showed a
34.4 ± 5.7-fold increase (n = 12) in miR-146a expression compared
with a much smaller 4.8 ± 0.5-fold (n = 12) elevation in miR-146b
level. Pre-treatment with the IKK-2 inhibitor (TPCA-1) caused a
concentration-dependent reduction in IL-1b-induced IL-8 and
RANTES release with IC50’s of 4.4 and 1.2 lM, respectively
Fig. 1. IL-1b-induced activation of IKK-2, ERK-1/2, JNK-1/2 and p38 MAP kinase inhibition in human alveolar A549 epithelial cells. A549 cells were stimulated for the
indicated time with IL-1b (1 ng/ml). Total protein was then extracted and the levels of IjBa, total and phospho-ERK-1/2, total and phospho-JNK-1/2, total and phospho-p38
MAP kinase and b-actin were detected by Western blotting (A). In panel B, changes in the IjBa and phospho-MAP kinase expression were quantitated by densitometry,
normalized against b-actin expression and then expressed as the % change versus untreated vehicle controls (IjBa) or versus time-matched non-phosphorylated controls
(MAP kinases). Results are the mean ± S.E.M. of three independent experiments.
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tion in miR-146a (Fig. 3A) but not miR-146b (Fig. 3B) expression as
the concentration of TPCA-1 was increased from 1 to 10 lM. In
contrast, the MEK inhibitor PD98059 had no effect upon either
IL-8 or RANTES release (Fig. 2C and D) or miR-146a expression
(Fig. 3C) at concentrations up to 10 lM but signiﬁcantly reduced
the expression of miR-146b between 1 and 10 lM (Fig. 3D). Inhibi-
tion of JNK-1/2 using SP600125 (0.1–10 lM) resulted in a concen-
tration dependent decrease in IL-8 and RANTES release with IC50’s
of 0.94 and 0.92 lM, respectively (Fig. 2E and F) and inhibition of
miR-146a at 10 lM (lM) (Fig. 3E). In addition, SP600125 also
attenuated IL-1b-induced miR-146b expression and this was seen
at both 1 and 10 lM (Fig. 3F). Finally, studies using the p38 MAP
kinase inhibitor SB 203580 showed no effect upon either IL-1b-in-
duced IL-8 and RANTES generation (Fig. 2G and H) or miR-146a and
miR-146b expression (Fig. 3G and H).4. Discussion
Recent studies have demonstrated the rapid induction in the
expression of miR-146a and miR-146b following activation of the
innate immune response by plasma membrane associated mem-
bers of the TLR/IL-1 receptor superfamily [13,19]. Functional stud-
ies indicate that increased miR-146a and miR-146b expression is
involved in the negative regulation of the TLR/IL-1 receptorinduced inﬂammatory response [13,19,34]. However, a number
of reports have indicated that miR-146a expression is regulated
via NF-jB [13,19,34–36], even though nothing is known about
the mechanisms that regulate miR-146b expression. In addition,
it is unclear whether miR-146a and/or miR-146b transcription is
also regulated by members of the MAP kinase family, which are
also commonly activated via the TLR/IL-1 receptors. To address this
question, we employed a pharmacological based approach to
investigate the role of the MAP kinases; MEK-1/2, JNK-1/2 and
p38 MAP kinase during IL-1b-induced miR-146a and miR-146b
expression in the human alveolar A549 epithelial cells. In addition,
we have used an IKK-2 inhibitor to examine the role of NF-jB and
determined how these pathways inﬂuence the expression of the
inﬂammatory chemokines, IL-8 and RANTES.
As previously reported, IL-1b-induced both miR-146a and miR-
146b expression and IL-8 and RANTES release from human alveolar
A549 epithelial cells [19]. Using Western blotting, we demon-
strated that IL-1b exposure induced rapid and transient degrada-
tion of IjBa. Previous investigations in human alveolar A549
epithelial cells indicate that IjBa degradation occurs following
phosphorylation by activated IKK-2, that leads to the subsequent
nuclear translocation of activated NF-jB [47–49]. To assess the role
of NF-jB during miR-146a and miR-146b transcription, we there-
fore examined the effect of the IKK-2 selective inhibitor TPCA-1
[39,40]. These studies showed that IL-1b-induced miR-146a
expression was mediated via the IKK-2–IjBa–NF-jB pathway
Fig. 2. Effect of IKK-2, MEK-1/2, JNK-1/2 and p38 MAP kinase inhibition upon IL-1b induced IL-8 and RANTES release in human alveolar A549 epithelial cells. A549 cells were
pre-treated for 60 min with the indicated concentrations of the inhibitors of IKK-2 (A/B), MEK-1/2 (C/D), JNK-1/2 (E/F) and p38 MAP kinase (G/H). Following stimulation with
IL-1b (1 ng/ml) for 24 h, the levels of IL-8 (A/C/E/G) and RANTES (B/D/F/H) in the supernatant was measured by ELISA. Results are the mean ± S.E.M. of three independent
experiments where ***P < 0.001 versus time- and vehicle-matched controls.
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inhibitor. However, the IKK-2 inhibitor had no effect upon IL-1b-
stimulated miR-146b expression which implied that miR-146b
transcription was not mediated via NF-jB. A role for NF-jB in
miR-146a transcription has previously been reported by a numberof investigators [13,19,34–36]. In particular, Taganov et al. [13]
identiﬁed three consensus binding sites for NF-jB in the upstream
promoter region of the primary miR-146a transcript and demon-
strated that site-directed mutagenesis attenuated LPS-, TNFa and
IL-1b-induced miR-146a expression. Interestingly, this report also
Fig. 3. Effect of IKK-2, MEK-1/2, JNK-1/2 and p38 MAP kinase inhibition upon IL-1b induced miR-146a and miR-146b expression in human alveolar A549 epithelial cells. A549
cells were pre-treated for 60 min with the indicated concentrations of the inhibitors of IKK-2 (A/B), MEK-1/2 (C/D), JNK-1/2 (E/F) and p38 MAP kinase (G/H). Following
stimulation with IL-1b (1 ng/ml) for 24 h, the cellular expression of miR-146a (A/C/E/G) and miR-146b (B/D/F/H) was measured by TaqMan RT-PCR. Results are the
mean ± S.E.M. of three independent experiments where *P < 0.05, **P < 0.01 and ***P < 0.001 versus time- and vehicle-matched controls.
M.M. Perry et al. / FEBS Letters 583 (2009) 3349–3355 3353identiﬁed a potential NF-jB binding site in the promoter region of
miR-146b although our studies would suggest that this is not in-
volved in the IL-1b mediated response [13].At the present time, little is known regarding the role of the
MAP kinases pathways in the regulation of miR-146a and miR-
146b transcription. Previous studies of miR-155 transcription,
3354 M.M. Perry et al. / FEBS Letters 583 (2009) 3349–3355another miRNA that is implicated in the immune response, have
indicated a role for JNK in polyI:C stimulated murine macrophages
[14] and for ERK and JNK (but not p38 MAP kinase) during BCR-in-
duced activation of the Ramos B-cell line [50]. Using phospho-anti-
bodies, we were able to demonstrate that IL-1b stimulated the
rapid and transient activation of the MAP kinases, ERK-1/2, JNK-
1/2 and p38 MAP kinase. Using selective inhibitors, we proceeded
to show that transcription of miR-146a and miR-146b is regulated
via different MAP kinase pathways. Thus, in addition to NF-jB, IL-
1b-induced miR-146a expression was regulated via a JNK-1/2-
dependent mechanism. In contrast, although miR-146b expression
occurred independently of NF-jB, we have shown that this process
is mediated via a JNK-1/2- and MEK-1/2-dependent mechanism.
Interestingly, neither miR-146a nor miR-146b expression was sen-
sitive to the p38 MAP kinase inhibitor, SB203580. Examination of
the pathways that regulate IL-8 and RANTES release indicate that
the transcription of these pro-inﬂammatory chemokines is medi-
ated via a similar mechanism to miR-146a, i.e. via an NF-kB- and
JNK-1/2-dependent mechanism.
Overall, these studies demonstrate that IL-1b-induced miR-
146a and miR-146b transcription is mediated via divergent intra-
cellular pathways and we speculate that this impacts upon the dif-
ferential expression and biological action of the miR-146 isoforms
in inﬂammation and the development of cancer.Acknowledgements
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